JP2025528101A - 多重特異性ポリペプチド複合体 - Google Patents

多重特異性ポリペプチド複合体

Info

Publication number
JP2025528101A
JP2025528101A JP2025506960A JP2025506960A JP2025528101A JP 2025528101 A JP2025528101 A JP 2025528101A JP 2025506960 A JP2025506960 A JP 2025506960A JP 2025506960 A JP2025506960 A JP 2025506960A JP 2025528101 A JP2025528101 A JP 2025528101A
Authority
JP
Japan
Prior art keywords
pair
polypeptide
domain
amino acid
psr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025506960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025528101A5 (https=
Inventor
ジョウ，ジェンハオ
ジャーン，ジエ
ワン，ゴン
Original Assignee
シャンハイ・カイジン・バイオテクノロジー，リミテッド
チマゲン・バイオサイエンシズ，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ・カイジン・バイオテクノロジー，リミテッド, チマゲン・バイオサイエンシズ，リミテッド filed Critical シャンハイ・カイジン・バイオテクノロジー，リミテッド
Publication of JP2025528101A publication Critical patent/JP2025528101A/ja
Publication of JP2025528101A5 publication Critical patent/JP2025528101A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2025506960A 2022-08-05 2023-02-07 多重特異性ポリペプチド複合体 Pending JP2025528101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/110697 2022-08-05
CN2022110697 2022-08-05
PCT/CN2023/074836 WO2024027120A1 (en) 2022-08-05 2023-02-07 Multi-specific polypeptide complexes

Publications (2)

Publication Number Publication Date
JP2025528101A true JP2025528101A (ja) 2025-08-26
JP2025528101A5 JP2025528101A5 (https=) 2026-02-17

Family

ID=89848477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025506960A Pending JP2025528101A (ja) 2022-08-05 2023-02-07 多重特異性ポリペプチド複合体

Country Status (6)

Country Link
EP (1) EP4565620A1 (https=)
JP (1) JP2025528101A (https=)
CN (1) CN119998329A (https=)
AU (1) AU2023318846A1 (https=)
CA (1) CA3263920A1 (https=)
WO (1) WO2024027120A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177643B1 (en) * 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
WO2017055392A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
WO2017055314A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
KR102692708B1 (ko) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CR20210330A (es) * 2018-12-21 2021-07-20 Hoffmann La Roche ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
CA3124688A1 (en) * 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
WO2020156405A1 (en) * 2019-01-28 2020-08-06 Wuxi Biologics (Shanghai) Co. Ltd. Novel bispecific cd3/cd20 polypeptide complexes
IL302412A (en) * 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies

Also Published As

Publication number Publication date
AU2023318846A1 (en) 2025-02-27
CN119998329A (zh) 2025-05-13
WO2024027120A1 (en) 2024-02-08
EP4565620A1 (en) 2025-06-11
CA3263920A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP2023061969A (ja) Ｓｉｒｐ－アルファドメインまたはそのバリアントを有する構築物
CN116888153A (zh) 与γ-δT细胞受体结合的抗体
WO2024131962A1 (zh) 新型抗gprc5d抗体
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
US20240182576A1 (en) Heterodimeric antibodies and antigen-binding fragment thereof
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
CN112789058A (zh) 双特异性抗体构建体的下游加工
JP2023548345A (ja) クリッピング率の低減した抗原結合ドメイン
JP2023547661A (ja) Ｃｄ３に結合するポリペプチド構築物
WO2024027120A1 (en) Multi-specific polypeptide complexes
WO2024149381A1 (en) Multi-specific polypeptide complexes
WO2025026282A1 (en) Modified type e multi-specific antibodies
WO2024027828A1 (en) Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
WO2025092987A9 (zh) 基于Fc区的异二聚体分子及其用途
WO2023011650A1 (zh) 一种多特异性抗体及其用途
JP2025542322A (ja) Ｇｐｒｃ５ｄを標的とする多重特異性ポリペプチド複合物
HK1257372B (zh) 具有SIRP-α结构域或其变体的构建体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260206